首页> 外文OA文献 >Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

【2h】

Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

机译：I阶段研究S-Trans，Trans-Farneryylthiosylic acid（Salirasib），一种新型口腔RAS抑制剂，令人难以忍受的血液学恶性肿瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Talha Badar; Jorge E. Cortes; Farhad Ravandi; Susan OBrien; Srdan Verstovsek; Guillermo Garcia-Manero; Hagop Kantarjian; Gautam Borthakur;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies [J] . Badar Talha, Cortes Jorge E., Ravandi Farhad, Clinical lymphoma, myeloma & leukemia . 2015,第7期

机译：难治性血液系统恶性肿瘤患者的新型口服RAS抑制剂S-Trans，Farnesylthiosalicylic acid（Salirasib）的I期研究
2. Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors [J] . Apostolia Maria Tsimberidou, Michelle A. Rudek, David Hong, Cancer Chemotherapy and Pharmacology . 2010,第2期

机译：S-反式，反法尼基硫代水杨酸（salirasib）在实体瘤患者中的1期首次人类临床研究
3. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies [J] . Ogura Michinori, Uchida Toshiki, Terui Yasuhito, Cancer science. . 2015,第7期

机译：复发/难治性血液系统恶性肿瘤患者口服信号转导和转录激活因子抑制剂OPB-51602的I期研究
4. Designing a conversational agent for patients with hematologic malignancies: Usability and Usefulness Study [C] . Maria Chatzimina, Helen Papadaki, Charalampos Pontikoglou, IEEE EMBS International Conference on Biomedical and Health Informatics . 2021

机译：设计血液学恶性肿瘤患者的会话剂：可用性和有用性研究
5. The burden of parainfluenza virus infection in patients with hematological malignancy and hematopoietic stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of infection control. [D] . Hanmod, Santosh S. 2009

机译：在没有积极免疫和批准治疗的情况下，血液恶性肿瘤和造血干细胞移植（HSCT）患者的副流感病毒感染负担：感染控制的作用。
6. Phase I Study of S-trans Trans-farnesylthiosalicylic Acid (Salirasib) a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies [O] . Talha Badar, Jorge E Cortes, Farhad Ravandi, -1

机译：难治性血液系统恶性肿瘤患者的新型口服RAS抑制剂S-反式反式-法呢基硫代水杨酸（Salirasib）的I期研究
7. Phase I study of OPB ‐51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies [O] . Michinori Ogura, Toshiki Uchida, Yasuhito Terui, 2015

机译：患有复发/难治性血液恶性恶性肿瘤的患者，I阶段I研究OPB -51602，信号传感器和转录激活剂的激活剂3

Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

著录项

引文网络

相似文献

相关主题

期刊订阅